Denali Therapeutics (DNLI) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Vericel (VCEL) over the past year, gaining 28.6% versus a gain of 23.0%. Over five years, VCEL leads with a -19.8% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $2.09 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | VCEL |
|---|---|---|
| Share price | $19.16 | $40.74 |
| Market cap | $3.06B | $2.09B |
| 1-day change | -0.62% | +1.72% |
| YTD return | +16.05% | +13.14% |
| 1-year return | +28.59% | +23.04% |
| 5-year return | -57.95% | -19.79% |
| P/E ratio (TTM) | — | 86.68 |
| Forward P/E | — | 48.16 |
| EPS (TTM) | $-2.84 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $49.32 |
| 52-week low | $13.75 | $28.95 |
| Distance from 52-week high | -29.82% | -17.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +88.20% | +48.67% |
| Average volume | 1.61M | 503.13K |
| Shares outstanding | 159.85M | 51.21M |
| Employees | 503 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
DNLI vs VCEL FAQ
Which is bigger, Denali Therapeutics or Vericel?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $2.09B for Vericel (VCEL).
Which stock has performed better over the past year, DNLI or VCEL?
DNLI returned +28.59% over the past 12 months, compared with +23.04% for VCEL (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Vericel in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.